Ovid therapeutics inc. (OVID)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Operating expenses:
Research and development

47,445

42,157

38,706

35,653

34,652

33,790

31,848

29,203

27,162

49,972

47,248

44,048

39,743

9,585

0

0

0

General and administrative

20,204

19,251

18,550

18,014

18,902

19,141

19,014

17,893

17,012

15,035

0

0

0

-

0

0

-

Selling, general and administrative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Total operating expenses

67,649

61,408

57,257

53,667

53,555

52,931

50,863

47,096

44,175

65,007

61,548

57,954

53,082

22,535

0

0

0

Loss from operations

-67,650

-61,409

-57,257

-53,667

-53,555

-52,931

-50,863

-47,096

-44,175

-65,007

0

0

0

-

0

0

-

Interest income

959

948

865

948

957

951

823

659

425

201

141

120

111

120

0

0

0

Loss before income tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net loss

-66,689

-60,460

-56,392

-52,719

-52,597

-51,979

-50,039

-46,436

-43,750

-64,806

-61,407

-57,833

-52,970

-22,414

0

0

0

Net loss attributable to common stockholders

-66,689

-60,460

-56,392

-52,719

-52,597

-51,979

-50,039

-46,436

-43,750

-64,806

-61,407

-57,833

-52,970

-22,414

0

0

0

Net loss per share, basic and diluted

-

-0.35

-

-

-

-0.52

-

-

-

1.08

-0.38

-0.57

-3.48

-0.77

-0.59

-0.55

-0.37

Weighted-average shares outstanding basic and diluted

-

-

-

-

-

-

-

-

-

24,824

24,601

18,112

9,838

9,838

9,838

9,838

9,838

Common Stock [Member]
Net loss per share, basic and diluted

-0.37

-0.31

-0.43

-0.34

-0.46

-0.51

-0.53

-0.53

-0.54

-

-

-

-

-

-

-

-

Weighted-average shares outstanding basic and diluted

54,715

49,341

38,504

38,693

30,329

24,654

24,634

24,625

24,609

-

-

-

-

-

-

-

-